Key Points
The allocation will be utilised to augment the companys capabilities to meet growing demand efficiently and sustain long-term growth, the management told Business Today...
The pharma giant aims to achieve consolidated revenue between Rs 13,500 crore and Rs 14,000 crore, with a push towards market leadership and financial strength.. Officials said that the firm will invest significantly in research and development (R&D) to meet its revenue targetand has allocated 7-7.25percentof its total sales to R&D efforts...
It is expected to enhance Glenmarks competitive edge, fostering the discovery of new therapies and expanding its product portfolio, the company said.. Operationally, Glenmark is targeting an EBITDA margin of approximately 19percent..
The company is also eyeing a double-digit profit after tax (PAT) margin while focusing on sustainable financial performance to provide value to stakeholders, the company's management said.. Glenmarks formulation business remains integral to its global strategy, covering branded,genericsand over-the-counter (OTC) products in therapeutic areas like dermatology, respiratory, oncology, cardiac, diabetes, and oral contraceptives..
A breakdown of regional contribution showed the companys India business posting a healthy growth of 12.9percentto Rs 939.1 crore, while its Rest of the World (RoW) segment grew by 9.7percentto Rs 752.8 crore..
